$3516 | SAVE $479 | Single User
$7031 | SAVE $959 | Site License
$10547 | SAVE $1,438 | Enterprise License

EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023
[Published by Global Data]

Published by Global Data: 01 Dec 2015 | 17600 | In Stock
Related Topics: Pulmonary

Introduction

EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023

Summary

Chronic obstructive pulmonary disease (COPD), also known as chronic obstructive lung disease (COLD), is a condition characterized by difficulty breathing, shortness of breath, wheezing, chest tightness, and other respiratory symptoms that progress over time. The disease is often caused by smoking; however, long-term exposure to other lung irritants, such as pollution, smoke from vehicle emissions and power stations, chemical fumes, and dust, can also lead to the development of COPD. COPD is also a significant cause of morbidity and mortality, and the World Health Organization (WHO) predicts that it will be the third leading cause of death in the world by 2030.

In the 8MM, GlobalData epidemiologists forecast that the total prevalent cases of COPD will increase from 64,229,605 cases in 2013 to 73,794,089 cases in 2023 at an Annual Growth Rate (AGR) of 1.49%. GlobalData epidemiologists also forecast that the diagnosed prevalent cases of COPD will increase from 18,920,845 cases in 2013 to 21,789,454 cases in 2023 at an AGR of 1.52%. In the 8MM in 2013, 16.41% of the diagnosed prevalent cases of COPD were in GOLD Stage I, 24.66% were in GOLD Stage II, 29.09% were in GOLD Stage III, and 29.84% were in GOLD Stage IV. GlobalData epidemiologists estimated that 18,065,499 of the diagnosed prevalent cases of COPD in 2013 would have survived to the end of the year.

This analysis for COPD is a market-driven epidemiological report providing detailed segmentations of the COPD patient population, including the age- and sex-specific distribution of the total and diagnosed prevalent cases, the GOLD stage distributions for the total and diagnosed prevalent cases, the diagnosed prevalent cases that have comorbidities, and an estimation of the exacerbations and mortality for the forecast COPD patients. GlobalData epidemiologists also describe in detail the sources and methodology that were used in the forecast, thereby ensuring transparency of the forecasting process.

Scope

- The Chronic Obstructive Pulmonary Disease (COPD) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for COPD in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Australia). It includes a 10-year epidemiological forecast of the total prevalent cases of COPD and total diagnosed prevalent cases of COPD, segmented by age and sex. Additionally it provides segmentation of diagnosed prevalent cases by severity using the GOLD standard.

- The COPD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The COPD EpiCast report will allow you to -

- Develop business strategies by understanding the trends shaping and driving the global COPD market.

- Quantify patient populations in the global COPD market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for COPD therapeutics in each of the markets covered.

- Identify the COPD comorbidities that are most important to your marketing plans

Table of Contents
for EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023 [Published by Global Data]

  • 1 Table of Contents

    1 Table of Contents 4

    1.1 List of Tables 6

    1.2 List of Figures 7

    2 Introduction 8

    2.1 Catalyst 8

    2.2 Related Reports 9

    2.3 Upcoming Related Reports 9

    3 Epidemiology 10

    3.1 Disease Background 10

    3.2 Risk Factors and Comorbidities 11

    3.3 Global Trends 13

    3.3.1 US 13

    3.3.2 5EU 14

    3.3.3 Japan and Australia 15

    3.4 Forecast Methodology 15

    3.4.1 Sources Used 18

    3.4.2 Sources Not Used 33

    3.4.3 Forecast Assumptions and Methods 34

    3.5 Epidemiological Forecast for COPD (2013-2023) 39

    3.5.1 Total Prevalent Cases of COPD 39

    3.5.2 Age-Specific Total Prevalent Cases of COPD 41

    3.5.3 Sex-Specific Total Prevalent Cases of COPD 43

    3.5.4 Age-Standardized Total Prevalence of COPD 45

    3.5.5 Total Prevalent Cases of COPD by the GOLD Severity Stage 46

    3.5.6 Diagnosed Prevalent Cases of COPD 47

    3.5.7 Age-Specific Diagnosed Prevalent Cases of COPD 49

    3.5.8 Sex-Specific Diagnosed Prevalent Cases of COPD 51

    3.5.9 Age-Standardized Diagnosed Prevalence of COPD 53

    3.5.10 Diagnosed Prevalent Cases of COPD by the GOLD Severity Stage 54

    3.5.11 Diagnosed Prevalent Cases of COPD with Comorbidities 55

    3.5.12 Diagnosed Prevalent Cases of COPD Surviving to One Year 56

    3.6 Discussion 58

    3.6.1 Epidemiological Forecast Insight 58

    3.6.2 Limitations of the Analysis 59

    3.6.3 Strengths of the Analysis 59

    4 Appendix 60

    4.1 Bibliography 60

    4.2 Physicians and Specialists Included in this Study 65

    4.3 About the Authors 68

    4.3.1 Epidemiologists 68

    4.3.2 Reviewers 68

    4.3.3 Global Director of Therapy Analysis and Epidemiology 69

    4.3.4 Global Head of Healthcare 70

    4.4 About GlobalData 71

    4.5 About EpiCast 71

    4.6 Disclaimer 72

List Of Tables
in EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023 [Published by Global Data]

1.1 List of Tables

Table 1: Risk Factors and Comorbidities for COPD 12

Table 2: GOLD COPD Severity Diagnostic Criteria 16

Table 3: 8MM, Sources Used to Forecast the Total Prevalent Cases of COPD 18

Table 4: 8MM, Sources Used to Determine the Severity Segmentation Among the Total Prevalent Cases of COPD 19

Table 5: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of COPD Via the Diagnosis Rate 20

Table 6: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of COPD Via the Diagnosed Prevalence Rate 21

Table 7: 8MM, Sources Used to Forecast the Prevalent Cases of Comorbidities Among the Diagnosed Prevalent Cases of COPD 22

Table 8: 8MM, Sources Used to Forecast the GOLD Severity Among the Diagnosed Prevalent Cases of COPD 24

Table 9: 8MM, Sources Used to Forecast the Exacerbations and Mortality Among the Diagnosed Prevalent Cases of COPD by the GOLD Stage 25

Table 10: 8MM, Total Prevalent Cases of COPD, Both Sexes, Ages ≥35 Years, N, Selected Years, 2013-2023 40

Table 11: 8MM, Age-Specific Total Prevalent Cases of COPD, Both Sexes, N (Row %), 2013 42

Table 12: 8MM: Sex-Specific Total Prevalent Cases of COPD, Ages ≥35 Years, N (Row %), 2013 44

Table 13: 8MM, Total Prevalent Cases of COPD by the GOLD Severity Stage, Both Sexes, Ages ≥35 Years, N (Row %), 2013 47

Table 14: 8MM, Diagnosed Prevalent Cases of COPD, Both Sexes, Ages ≥35 Years, N, Selected Years, 2013-2023 48

Table 15: 8MM, Age-Specific Diagnosed Prevalent Cases of COPD, Both Sexes, N (Row %), 2013 50

Table 16: 8MM: Sex-Specific Diagnosed Prevalent Cases of COPD, Ages ≥35 Years, N (Row %), 2013 52

Table 17: 8MM, Diagnosed Prevalent Cases of COPD by the GOLD Severity Stage, Both Sexes, Ages ≥35 Years, N (Row %), 2013 55

Table 18: 8MM, Comorbidities Among the Diagnosed Prevalent Cases of COPD, Both Sexes, Ages ≥35 Years, N, 2013 56

Table 19: 8MM, Diagnosed Prevalent COPD Cases Experiencing Exacerbations and Mortality, Both Sexes, Ages ≥35, N, 2013 57

List Of Figures, Charts and Diagrams
in EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023 [Published by Global Data]

1.2 List of Figures

Figure 1: 8MM, Forecast Methodology Case Flow Overview 17

Figure 2: 8MM, Total Prevalent Cases of COPD, Both Sexes, Ages ≥35 Years, N, Selected Years, 2013-2023 40

Figure 3: 8MM, Age-Specific Total Prevalent Cases of COPD, Both Sexes, N, 2013 43

Figure 4: 8MM, Sex-Specific Total Prevalent Cases of COPD, Ages ≥35 Years, N, 2013 45

Figure 5: 8MM, Age-Standardized Total Prevalence of COPD (%), 2013 46

Figure 6: 8MM, Diagnosed Prevalent Cases of COPD, Both Sexes, Ages ≥35 Years, N, Selected Years, 2013-2023 49

Figure 7: 8MM, Age-Specific Diagnosed Prevalent Cases of COPD, Both Sexes, N (Row %), 2013 51

Figure 8: 8MM, Sex-Specific Diagnosed Prevalent Cases of COPD, Ages ≥35 Years, 2013 53

Figure 9: 8MM, Age-Standardized Diagnosed Prevalence of COPD (%), Both Sexes, Ages ≥35 Years, 2013 54

Figure 10: 8MM, Diagnosed Prevalent COPD Cases Experiencing Mortality, Both Sexes, Ages ≥35 Years, N, 2013 58

Additional Details

Publisher

Global Data

Publisher Information

Reference

17600 | GDHCER105-15

Number of Pages

73

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 12% today! EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024
EpiCast Report: Non-Hodgkin’s Lymphoma - Epidemiology Forecast to 2024SummaryNon-Hodgkin’s Lymphoma ...
01 Jan 2016 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024
EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2024SummaryPulmonary Arte...
01 Jan 2016 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024
EpiCast Report: Small Cell Lung Cancer - Epidemiology Forecast to 2024SummarySmall Cell Lung Cancer ...
01 Jan 2016 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Vasculitis - Epidemiology Forecast to 2024
EpiCast Report: Vasculitis - Epidemiology Forecast to 2024SummaryVasculitis is a group of heterogene...
01 Jan 2016 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024
EpiCast Report: Chronic Hepatitis B - Epidemiology Forecast to 2024SummaryThe Hepatitis B Virus (HBV...
24 Dec 2015 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024
EpiCast Report: Respiratory Syncytial Virus Infection - Epidemiology Forecast to 2024SummaryRSV is a...
23 Dec 2015 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024
EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024SummarySjögren’s syndrome (SS) is ...
09 Dec 2015 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Huntington’s Disease - Epidemiology Forecast to 2024
EpiCast Report: Huntington’s Disease - Epidemiology Forecast to 2024SummaryHuntington’s disease (HD)...
09 Dec 2015 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024
EpiCast Report: Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2024SummarySystemic scle...
09 Dec 2015 by Global Data USD $3,516 (normally
USD $3,995)
More Info
SAVE 12% today! EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024
EpiCast Report: Brain Cancer - Epidemiology Forecast to 2024SummaryPrimary brain cancer is defined a...
01 Dec 2015 by Global Data USD $3,516 (normally
USD $3,995)
More Info

This report is published by Global Data

Download Free Report Summary PDF

EpiCast Report: Chronic Obstructive Pulmonary Disease (COPD) - Epidemiology Forecast to 2023 [Published by Global Data] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...